The Clinical Evaluation Of The Combination Treatment With Endostar And GP Interventional Chemotherapy For NSCLC

Objetive the clinical evaluation and the antiangiogenesis effect of the combination interventional therapy for the advanced NSCLC with GP scheme and antiangiogenetic drug endostar, comparing with the GP scheme alone.Method 40 patients confirmed to be the stage III or IV NSCLC by the pathology method were divided to the experimental group, treated by the interventional therapy with GP and endostar, and the control group, with the GP alone, the general conditional difference of which tested to be of no existence. The judgement of this clinical experiment includes evaluation of the short term and the future. For the short term effect, each patient's maximum diameter is tested to find out the change of the maximum diameter and for RECIST clinical curative effect judgement. The tumor marker, the QOL socore and the theraputic side effects are also examined. The progression free survival analysis and the overall survival analysis were taken place with the Log-rank method together with the Cox proportional hazard model to check the risk factor. Theα=0.05 is taken to be the examinatonal level. Each patient had been informed consent before the curation, and the clinical experiment were screend to carry out by the ethics committee.Result Within groups. In the GP group, there is statistical difference at each check time in the maximum diameter, and the relationship of which is pre>3m>2m >1m. there is no statistically different discrepancy in the tumor marker change, and the the QOL is advanced as well as the gentle side reaction existing. While, in the GP and endostar group, statistical difference is shown in the maximum diameter, too, and the relavance of the maxium diameter is pre>1m>2m>3m. the tumor marker is obvious reduced and the QOL is tested to go up for patients. Similar to the GP alone group, the side effect of the therapy is mild without serious Cardiac toxicity. Between groups. Difference is shown in RECIST results (the the remission rates and clinical effective rates in the experimental group and the control group are 45%vs10% and 100%vs90%, respectively). At the same time, the median disease free time is 5.85months (5.194 months-6.506 months) in the GP group, and 7.5 months (6.012 months-8.988 months) in GP and endostar group, which exists statistical difference. While the median overall survival time is 12.660 months (10.727months-14.593months) in GP group, and 12.297months (10.372 months-14.223months) in GP and endostar group, which shows no statistacal difference. Cox proportional hazard model indicates that the use of endostar and the Zps score influence the TTP, however, the gender factors and the Zps are risky factors for the OS.Conclusion the preliminary clinical evaluation shows that there are better effects of the GP and endostar group in the maximum diameter, RECIST clinical judgement, the tumor marker, and the TTP than the GP group without serious side effects.